Ultrathin two-dimensional nanobelt tumor targeting contrast agent and preparation method and application thereof
The tumor-targeting contrast agent, prepared by the self-assembly of manganese ions and sodium risedronate using ultrathin two-dimensional nanoribbons, solves the safety and biodegradability issues of existing MRI contrast agents, achieving highly efficient MRI imaging and diagnostic accuracy.
Patent Information
- Application Number
- CN202410934890.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-22
AI Technical Summary
Existing MRI contrast agents, such as gadolinium-based contrast agents, pose a risk of kidney damage. The biodegradability and long-term retention of superparamagnetic iron oxide nanoparticles in vivo have not been fully resolved, affecting the safety and accuracy of imaging.
A tumor-targeting contrast agent using ultrathin two-dimensional nanoribbons was constructed by supramolecular self-assembly of manganese ions (Mn2+) and sodium risedronate. The preparation method included stirring, centrifugation, washing, and ultrasonic dispersion to obtain HSA-modified RMn-NBs nanoribbons.
It improves the T2-weighted effect of MRI imaging, enhances hydrogen proton relaxation ability, has higher biocompatibility and in vivo metabolism, and is superior to commercial contrast agent Fe3O4, significantly improving imaging quality and diagnostic accuracy.
Smart Images

Figure CN118987286A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to an imaging diagnostic contrast agent, in particular to an ultra-thin two-dimensional nanobelt tumor-targeting contrast agent and a preparation method and application thereof. Background Art
[0002] Magnetic resonance imaging (MRI) is a non-invasive imaging technique widely used in medical diagnosis and biomedical research. Its imaging principle is based on the absorption and re-emission of radio frequency energy by atomic nuclei in an external magnetic field, thereby obtaining high-resolution images of internal tissue structures. In order to enhance the imaging effect of MRI, contrast agents are often used to increase the signal difference between the target tissue and the surrounding tissue. At present, common MRI contrast agents mainly include paramagnetic and superparamagnetic materials. Gadolinium (Gd)-based contrast agents are widely used in clinical practice due to their strong paramagnetism. However, gadolinium-based contrast agents may cause safety issues such as renal damage during metabolism in the body. In addition, superparamagnetic iron oxide nanoparticles (SPIONs) have also been widely studied and have high T2-weighted imaging effects, but their biodegradability and long-term retention in the body have not been completely solved.
[0003] With the development of nanotechnology, nanomaterials have shown great potential in the field of medical imaging due to their unique physical and chemical properties. Two-dimensional nanomaterials have become a new hot spot in the research of MRI contrast agents due to their high surface area, excellent electronic and magnetic properties. In particular, transition metal phosphate two-dimensional nanobelts have become a research object of great concern due to their unique magnetic properties and biocompatibility. As a new type of two-dimensional nanomaterial, risedronate manganese (RMn-NBs) exhibits excellent magnetic and biological properties. RMn-NBs two-dimensional nanobelts not only have good paramagnetism, but also can improve the T2-weighted imaging effect of MRI to a certain extent. In addition, RMn-NBs have good water solubility and biodegradability, can be safely metabolized in vivo, and reduce the potential toxicity risk. RMn-NBs showed significant T2-weighted imaging enhancement in in vitro and in vivo experiments. Its unique two-dimensional structure provides a larger surface area, which is conducive to the combination and functional modification of biological molecules, further improving its imaging performance and biocompatibility. This makes RMn-NBs two-dimensional nanobelts show broad application prospects in the field of MRI contrast agents.
[0004] In summary, RMn-NBs two-dimensional nanobelts, as a new type of MRI contrast agent, have significant technical advantages and application potential. Its application in magnetic resonance imaging is expected to not only improve imaging quality, but also improve diagnostic accuracy and safety, and promote the development of medical imaging technology. Summary of the invention
[0005] The purpose of the present invention is to solve the shortcomings of the prior art and provide an ultra-thin two-dimensional nanoribbon tumor-targeted contrast agent and a preparation method thereof and an application thereof in in vivo imaging.
[0006] The technical solution adopted by the present invention is:
[0007] Ultrathin two-dimensional nanoribbon tumor-targeted contrast agent composed of manganese ions Mn 2+ It is constructed with risedronate sodium using supramolecular self-assembly.
[0008] Furthermore, the structural formula of the supramolecular self-assembly is as follows:
[0009]
[0010] Furthermore, the contrast agent is a two-dimensional nanoribbon with a width of 5 to 10 nm and a length of 150 to 200 nm, wherein risedronate sodium: Mn 2+ The amount ratio of the chemical substances is 1:(1 to 5).
[0011] Furthermore, the molar concentration of risedronate sodium is 10 mM, pH = 7.4; Mn 2+ The molar concentration is 10mM; risedronate sodium: Mn 2+ The added volume ratio satisfies 1:(1~5).
[0012] The preparation method of the tumor-targeted contrast agent of the ultrathin two-dimensional nanobelt comprises the following steps: preparing risedronate sodium into a risedronate sodium solution, and then adding a certain concentration of Mn 2+ The solution is stirred, and two-dimensional nanobelts RMn-NBs are obtained by centrifugal separation, washing and ultrasonic dispersion.
[0013] Furthermore, the preparation method comprises the following specific steps:
[0014] Risedronate sodium and Mn 2+ The stirring and mixing time was 6 hours, and the nanoscale crude product was obtained by centrifugation at 8000g×30min. It was then washed with deionized water 3 times, 10mL each time, to remove free drug monomers, and then centrifuged at 12000rpm×10min to obtain a nanoscale pure solid product. Finally, human serum albumin HSA was used as an emulsifier and aggregation inhibitor, and 10mL of an aqueous solution containing 2% HSA was added. Ultrasound was performed at 650W power and 45% intensity for 12 minutes to obtain HSA-modified RMn-NBs.
[0015] Ultrathin two-dimensional nanoribbons as tumor-targeted contrast agents for magnetic resonance imaging.
[0016] The beneficial effects obtained by the present invention are: Mn 2+It is a paramagnetic metal ion that can enhance the relaxation of hydrogen protons. The two-dimensional nanobelts Risedronate-Manganese Nanobelts (abbreviated as RMn-NBs) with nuclear magnetic resonance imaging function prepared by the present invention have a higher T2 relaxation ability, and its nuclear magnetic resonance imaging ability is better than that of the commercial contrast agent Fe3O4, and has higher biosafety. Compared with the commercial Fe3O4 nuclear magnetic resonance contrast agent, the ultra-thin two-dimensional nanobelts RMn-NBs of the present invention have changes in transverse and longitudinal relaxation rates and their ability to enhance nuclear magnetic resonance imaging effects in mice. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 A high-resolution transmission electron microscope photograph of the two-dimensional nanoribbon RMn-NBs of the present invention;
[0018] Figure 2 is a particle size distribution diagram of the two-dimensional nanobelt RMn-NBs of the present invention;
[0019] Figure 3 This is the infrared spectrum of the two-dimensional nanobelt RMn-NBs of the present invention;
[0020] Figure 4 is the powder crystal diffraction spectrum of the two-dimensional nanobelt RMn-NBs of the present invention;
[0021] Figure 5 is the X-ray photoelectron spectrum of the two-dimensional nanoribbon RMn-NBs of the present invention;
[0022] Figure 6 is the longitudinal relaxation rate (r1) of the two-dimensional nanoribbon RMn-NBs of the present invention and the commercial Fe3O4 contrast agent;
[0023] Figure 7 is the transverse relaxation rate (r2) of the two-dimensional nanoribbon RMn-NBs of the present invention and the commercial Fe3O4 contrast agent;
[0024] Figure 8 The in vitro nuclear magnetic resonance imaging images of the two-dimensional nanobelt RMn-NBs of the present invention and the commercial Fe3O4 contrast agent;
[0025] Fig. 9 This is the nuclear magnetic resonance imaging image of the two-dimensional nanobelt RMn-NBs contrast agent of the present invention in BALB / c tumor-bearing mice;
[0026] Fig.10 The relative MRI signal intensity of the tumor and kidney regions of the two-dimensional nanoribbon RMn-NBs of the present invention at different time points. DETAILED DESCRIPTION
[0027] The following examples are used to illustrate the present invention. The raw materials therein are prepared in the laboratory, but they do not affect the scope of protection of the present invention to the claims.
[0028] Ultrathin two-dimensional nanoribbon tumor-targeted contrast agent composed of manganese ions Mn 2+ It is constructed with risedronate sodium using supramolecular self-assembly.
[0029] The structural formula of supramolecular self-assembly is as follows:
[0030]
[0031] The contrast agent is a two-dimensional nanoribbon with a width of 5 to 10 nm and a length of 150 to 200 nm. 2+ The molar ratio of the chemical substances is 1:(1-5). The molar concentration of risedronate sodium is 10 mM, pH=7.4; Mn 2+ The molar concentration is 10mM; risedronate sodium: Mn 2+ The added volume ratio satisfies 1:(1~5).
[0032] The preparation method of the tumor-targeted contrast agent of the ultrathin two-dimensional nanobelt comprises the following steps: preparing risedronate sodium into a risedronate sodium solution, and then adding a certain concentration of Mn 2+ The solution is stirred, and two-dimensional nanobelts RMn-NBs are obtained by centrifugal separation, washing and ultrasonic dispersion.
[0033] The preparation method comprises the following specific steps:
[0034] Risedronate sodium and Mn 2+ The stirring and mixing time was 6 hours, and the nanoscale crude product was obtained by centrifugation at 8000g×30min. It was then washed with deionized water 3 times, 10mL each time, to remove free drug monomers, and then centrifuged at 12000rpm×10min to obtain a nanoscale pure solid product. Finally, human serum albumin HSA was used as an emulsifier and aggregation inhibitor, and 10mL of an aqueous solution containing 2% HSA was added. Ultrasound was performed at 650W power and 45% intensity for 12 minutes to obtain HSA-modified RMn-NBs.
[0035] Ultrathin two-dimensional nanoribbons as tumor-targeted contrast agents for magnetic resonance imaging.
[0036] Example 1 Preparation of two-dimensional nanoribbon RMn-NBs
[0037] 10 mL of Risedronate solution (10 mM) and 10-50 mL of MnCl2 solution (10 mM) were carefully added to a 100 mL flask and then stirred at room temperature for 1 hour. After stirring for 6 hours, the formed precipitate was collected by centrifugation at 8000 g for 30 minutes and then washed three times with distilled water to remove impurities. Thereafter, the washed precipitate was dispersed in 10 mL of a solution containing 2% human serum albumin (HSA) as an emulsifier and aggregation inhibitor and subjected to ultrasonic treatment at a power of 650 W and an intensity of 45% for 12 minutes to obtain HSA-modified RMn-NBs.
[0038] Example 2 Electron microscopy and particle size characterization of two-dimensional nanoribbon RMn-NBs
[0039] The prepared two-dimensional nanobelt RMn-NBs was diluted 100 times and then dropped onto a carbon-coated support film (copper mesh). After being naturally dried, its morphology was observed using a high-resolution transmission electron microscope (HRTEM). The particle size of the solution was measured using a dynamic light scattering (DLS, Brookhaven 90plus Zeta) particle size analyzer. Figure 1 As shown in Figure 1, RMn-NBs are nanoribbon-shaped, with regular shapes and clear outlines, a length of about 150-200 nm, and a width of 5-10 nm. Figure 2 As shown, the average particle size measured by a dynamic light scattering particle size analyzer is 180 nm, which is consistent with the results of high-resolution field emission scanning electron microscopy.
[0040] Example 3 Infrared Characterization of Two-Dimensional Nanoribbon RMn-NBs
[0041] The infrared spectra of RMn-NBs were measured by FT-IR Fourier transform infrared spectrometer using freeze-dried RMn-NBs nanoribbon powder. Figure 3 As shown, Fourier transform infrared spectroscopy (FT-IR) confirmed the relationship between RANa and Mn 2+ The coordination relationship of RMn-NBs is MnCl2 (~1130cm -1 ) and RANa (~993,~1053and~1635cm -1 )’s characteristic absorption peak.
[0042] Example 4 Crystalline Characterization of Two-Dimensional Nanoribbon RMn-NBs
[0043] Powder crystal diffraction was performed by D8 Advanced XRD (Bruker, Germany) with Cu Kα radiation X-rays are obtained. Figure 4As shown, RMn-NBs has a certain crystal form and has characteristic absorption peaks at 2θ angles of 6.25°, 6.09°, 12.70°, 18.29°, 26.62°, 56.10°, and 61.56°.
[0044] Example 5 X-ray Photoelectron Spectroscopy Characterization of Two-Dimensional Nanoribbon RMn-NBs
[0045] The X-ray photoelectron spectrum of the two-dimensional nanobelt RMn-NBs was measured by a K-Alpha X-ray photoelectron spectrometer. X-ray photoelectron spectroscopy (XPS) confirmed the presence of metallic element manganese, with characteristic binding energies of 639.97 and 651.45 eV, which are similar to those of Mn. 2+ In addition, other non-metallic elements such as C, N, O, and P in RMn-NBs were further confirmed ( Figure 5 ).
[0046] Example 6 Determination of longitudinal relaxation rate of two-dimensional nanoribbons RMn-NBs as nuclear magnetic resonance imaging enhancers
[0047] Commercial contrast agent Fe3O4 and RMn-NBs samples were prepared at concentrations of 0.1μM, 0.2μM, 0.3μM, 0.4μM and 0.5μM, and T1-weighted and T2-weighted images of each sample were taken and quantified using a nuclear magnetic resonance imaging device (Biospec 7T / 20USR, Germany) at a magnetic field strength of 7.0 Tesla (T). Figure 6 As shown in Figure 2, under a magnetic field of 7.0 Tesla (T), the longitudinal relaxation rates (r1) of RMn-NBs and commercial Fe3O4 contrast agents are 0.5394 mM -1 s -1 and 0.3393mM -1 s -1 , the longitudinal relaxation rate of RMn-NBs is superior to that of commercial Fe3O4 contrast agents.
[0048] Example 7 Determination of transverse relaxation rate of two-dimensional nanoribbons RMn-NBs as nuclear magnetic resonance imaging enhancers
[0049] Commercial contrast agent Fe3O4 and RMn-NBs samples were prepared at concentrations of 0.1μM, 0.2μM, 0.3μM, 0.4μM and 0.5μM, and T1-weighted and T2-weighted images of each sample were taken and quantified using a nuclear magnetic resonance imaging device (Biospec 7T / 20USR, Germany) at a magnetic field strength of 7.0 Tesla (T). Figure 7 As shown in Figure 2, under a magnetic field of 7.0 Tesla (T), the transverse relaxation rates (r2) of RMn-NBs and commercial Fe3O4 contrast agents are 11.25 mM-1 s -1 and 11.17mM -1 s -1 , the transverse relaxation rate of RMn-NBs is superior to that of commercial Fe3O4 contrast agents.
[0050] Example 8 Determination of transverse relaxation rate of two-dimensional nanoribbons RMn-NBs as nuclear magnetic resonance imaging enhancers
[0051] Commercial contrast agent Fe3O4 and RMn-NBs samples were prepared at concentrations of 0.1μM, 0.5μM, 1μM, 2μM and 4μM, and T1-weighted and T2-weighted images of each sample were taken and quantified using a nuclear magnetic resonance imaging device (Biospec 7T / 20USR, Germany) at a magnetic field strength of 7.0 Tesla (T). Figure 8 As shown in Figure 2, the T2-weighted image of the RMn-NBs sample is darker than that of the commercial MRI contrast agent Fe3O4. At a magnetic field strength of 7.0T, the longitudinal relaxation rate (r1) and transverse relaxation rate (r2) of RMn-NB are 0.5394 mM, respectively. -1 s -1 and 11.25mM -1 s -1 These longitudinal and transverse relaxation rates are very close to the relaxation rates of commercial Fe3O4 (r1 = 0.3393 mM -1 s -1 , r2=11.17mM -1 s -1 ). The ratio of r2 to r1 (r2 / r1) of RMn-NBs was 20.86, indicating that RMn-NBs are excellent T2-weighted MRI contrast agents. Their T2-weighted MRI performance is slightly better than that of commercially available Fe3O4 contrast agents, and they are expected to be used to study their pharmacokinetic behavior in vivo.
[0052] Example 9 Evaluation of the MRI effect of two-dimensional nanoribbons RMn-NBs as MRI enhancers in BALB / c tumor-bearing mice
[0053] To evaluate the accumulation and MRI imaging ability of RMn-NBs in tumors and compare them with the commercial contrast agent Fe3O4, tumor-bearing (150-200 mm 3 ) mice were intravenously injected with samples of RMn-NBs containing the same concentration of contrast agent Fe3O4. Using a nuclear magnetic resonance imaging device (Biospec 7T / 20USR, Germany), different parts of the mice were imaged at 0, 2, 8, 16, 24, 48, and 72 hours. Fig. 9As shown in the figure, the MRI signal in the tumor site increased after intravenous injection of RMn-NB, reaching the maximum value 8 hours after intravenous injection, and then the MRI signal intensity gradually decreased within 16 to 72 hours. Within 24 hours after intravenous injection of RMn-NBs, the MRI signal intensity in the kidney gradually increased and decreased within 48 to 72 hours ( Fig.10 ). Magnetic resonance imaging showed that RMn-NBs had good accumulation and T2-weighted imaging effects in tumor tissues and could be slowly metabolized out of the body through the kidneys.
[0054] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.
Claims
1. Ultrathin two-dimensional nanoribbon tumor-targeted contrast agent, Features: The contrast agent is composed of Mn 2+ It is constructed with risedronate sodium using supramolecular self-assembly.
2. The tumor-targeting contrast agent of the ultrathin two-dimensional nanoribbon according to claim 1, Features: The structural formula of the supramolecular self-assembly is as follows:
3. The tumor-targeting contrast agent of the ultrathin two-dimensional nanoribbon according to claim 1, Features: The contrast agent is a two-dimensional nanobelt with a width of 5 to 10 nm and a length of 150 to 200 nm, wherein risedronate sodium: Mn 2+ The amount ratio of the chemical substances is 1:(1 to 5).
4. The tumor-targeting contrast agent of the ultrathin two-dimensional nanoribbon according to claim 3, Features: The molar concentration of risedronate sodium is 10 mM, pH = 7.4; Mn 2+ The molar concentration is 10mM; risedronate sodium: Mn 2+ The added volume ratio satisfies 1:(1~5).
5. Preparation method of ultrathin two-dimensional nanoribbon tumor-targeted contrast agent, Features: The following steps are involved: Prepare risedronate sodium into risedronate sodium solution, and then add a certain concentration of Mn 2+ The solution is stirred, and two-dimensional nanobelts RMn-NBs are obtained by centrifugal separation, washing and ultrasonic dispersion.
6. A method for preparing a tumor-targeting contrast agent of ultrathin two-dimensional nanoribbons according to claim 5, Features: The preparation method comprises the following specific steps: Risedronate sodium and Mn 2+ The stirring and mixing time was 6 hours, and the nanoscale crude product was obtained by centrifugation at 8000g×30min. It was then washed with deionized water for 3 times, 10mL each time, to remove free drug monomers, and then centrifuged at 12000rpm×10min to obtain a nanoscale pure solid product. Finally, human serum albumin was used as an emulsifier and aggregation inhibitor, and 10mL of an aqueous solution containing 2% human serum albumin was added. Ultrasound was performed at 650W power and 45% intensity for 12 minutes to obtain human serum albumin-modified RMn-NBs.
7. Application of ultrathin two-dimensional nanoribbon tumor-targeted contrast agents in magnetic resonance imaging.
